Abstract 435TiP
Background
Treatment with PD-L1 or PD-1 targeting antibodies is a cornerstone in cancer therapy, but not all patients benefit from these drugs. For most indications, the current reference biomarker is PD-L1 expression in a tumor biopsy, but this method has several disadvantages. Molecular imaging, such as PET/CT using receptor-specific radiotracers, offers non-invasive, real-time visualization of treatment targets. Previous trials have explored a few PD-L1/PD-1 radiotracers but lacked a systematic approach focused on a single tumor type and standardized clinical management.
Trial design
The MIMIR-trial (EU CT 2022-500808-21-00, NCT05742269) involves newly diagnosed mTNBC patients planned for first-line systemic treatment. Participants undergo a PD-L1 PET/CT scan with [89Zr]Zr-atezolizumab followed by a biopsy, with results guiding subsequent treatment with chemotherapy (carboplatin and nab-paclitaxel), combined with atezolizumab based on PD-L1 status as determined by IHC and/or PET. Treatment effectiveness is assessed bi-monthly, and therapy is continued until disease progression or unmanageable toxicity. The primary aim is to determine the statistical concordance (Cohen’s kappa coefficient) between PD-L1 status by PET and IHC. To target a kappa of 0.80 with a precision of +/- 0.15, 64 patients are required in this study. Secondary objectives include evaluating the predictive value of PD-L1 PET for treatment response and development of immunotherapy-mediated toxicity. Tissue, feces, and blood samples are collected for further translational analysis. The trial is ongoing at Karolinska University Hospital in Stockholm, Sweden, with three patients enrolled so far. An additional cohort of patients with non small cell lung cancer will be opened during Q3-4 2024.
Clinical trial identification
EU CT 2022-500808-21-00, NCT05742269.
Editorial acknowledgement
Legal entity responsible for the study
Karolinska University hospital, Region Stockholm, Sweden.
Funding
Roche Sweden AB.
Disclosure
J. Bergh: Non-Financial Interests, Personal, Advisory Board: stratipath. All other authors have declared no conflicts of interest.
Resources from the same session
375P - Results from the Danish Breast Cancer Group's (DBCG) NAME-trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic breast cancer
Presenter: Anne Sofie Brems-Eskildsen
Session: Poster session 15
376P - Evaluating adherence to oral anticancer medications in metastatic and non-metastatic breast cancer patients
Presenter: Rana El-Shewy
Session: Poster session 15
377P - Phase II study of trifluridine/tipiracil in pre-treated patients with ER-positive, HER2-negative metastatic breast cancer: A Dutch BOOG (2019-01 TIBET) study
Presenter: Niels Guchelaar
Session: Poster session 15
378P - Updated data on real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab
Presenter: Duan Yang
Session: Poster session 15
379P - Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic breast cancer: A multicentre international retrospective cohort study
Presenter: Luca Visani
Session: Poster session 15
381P - Treatment rechallenge after grade 1 trastuzumab-deruxtecan related interstitial lung disease: A real-world experience
Presenter: Kelsey Natsuhara
Session: Poster session 15
382P - Pyrotinib combined with metronomic oral etoposide (VP-16) in heavily pretreated HER2-positive metastatic breast cancer: A single-arm, phase II study
Presenter: Jiaxuan Liu
Session: Poster session 15